Q2 Earnings Estimate for HURA Issued By Zacks Small Cap

TuHURA Biosciences (NASDAQ:HURA) – Stock analysts at Zacks Small Cap issued their Q2 2025 EPS estimates for TuHURA Biosciences in a report released on Tuesday, February 4th. Zacks Small Cap analyst J. Vandermosten forecasts that the company will post earnings per share of ($0.09) for the quarter. Zacks Small Cap also issued estimates for TuHURA Biosciences’ Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.15) EPS, Q1 2026 earnings at ($0.17) EPS and Q2 2026 earnings at ($0.17) EPS.

Several other research firms also recently weighed in on HURA. Rodman & Renshaw initiated coverage on shares of TuHURA Biosciences in a research report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price target on the stock. RODMAN&RENSHAW upgraded shares of TuHURA Biosciences to a “strong-buy” rating in a research report on Thursday, December 19th. Finally, Maxim Group started coverage on shares of TuHURA Biosciences in a research report on Tuesday, November 5th. They issued a “buy” rating and a $15.00 price target on the stock.

TuHURA Biosciences Stock Performance

HURA opened at $4.88 on Wednesday. TuHURA Biosciences has a 1-year low of $2.84 and a 1-year high of $14.60. The stock has a 50 day simple moving average of $4.81.

Institutional Trading of TuHURA Biosciences

A hedge fund recently bought a new stake in TuHURA Biosciences stock. Apollon Wealth Management LLC acquired a new stake in shares of TuHURA Biosciences (NASDAQ:HURA) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 61,772 shares of the company’s stock, valued at approximately $253,000. Apollon Wealth Management LLC owned 0.15% of TuHURA Biosciences at the end of the most recent reporting period. Hedge funds and other institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.